GI Alliance - Garland
Welcome,         Profile    Billing    Logout  
 6 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hou, Jason K
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Recruiting
N/A
15000
US
Target PharmaSolutions, Inc.
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
10/25
10/25
QUOTIENT, NCT05230173: Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Recruiting
N/A
250
US
Pragmatic
University of California, San Diego, Baylor College of Medicine, Crohn's and Colitis Foundation, Western University, Patient-Centered Outcomes Research Institute
Ulcerative Colitis, Crohn Disease
03/28
06/28
MAAIS, NCT01169194: Multi-Center African-American Inflammatory Bowel Disease Study

Recruiting
N/A
2400
US
Johns Hopkins University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Inflammatory Bowel Disease
08/27
08/27
Sarles, Harry
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
NCT06109441: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Recruiting
2
30
US
ALTB-268
AltruBio Inc.
Ulcerative Colitis
10/25
11/26
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
Abraham, Bincy P
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
Kariyawasam, Viraj
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT04977063: Atmo SmartPill Comparison in Gastroparetic and Slow Transit Constipation Patients

Completed
N/A
53
RoW
Atmo gas capsule, SmartPill
Atmo Biosciences Pty Ltd, University of Western Sydney
Gastroparesis, Slow Transit
03/23
03/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hou, Jason K
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Recruiting
N/A
15000
US
Target PharmaSolutions, Inc.
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
10/25
10/25
QUOTIENT, NCT05230173: Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Recruiting
N/A
250
US
Pragmatic
University of California, San Diego, Baylor College of Medicine, Crohn's and Colitis Foundation, Western University, Patient-Centered Outcomes Research Institute
Ulcerative Colitis, Crohn Disease
03/28
06/28
MAAIS, NCT01169194: Multi-Center African-American Inflammatory Bowel Disease Study

Recruiting
N/A
2400
US
Johns Hopkins University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Inflammatory Bowel Disease
08/27
08/27
Sarles, Harry
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
NCT06109441: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Recruiting
2
30
US
ALTB-268
AltruBio Inc.
Ulcerative Colitis
10/25
11/26
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
Abraham, Bincy P
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
Kariyawasam, Viraj
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT04977063: Atmo SmartPill Comparison in Gastroparetic and Slow Transit Constipation Patients

Completed
N/A
53
RoW
Atmo gas capsule, SmartPill
Atmo Biosciences Pty Ltd, University of Western Sydney
Gastroparesis, Slow Transit
03/23
03/23

Download Options